castle biosciences, inc. specializes in diagnostic tests for cancers. founded in 2008, the company goal has been to help advance the care for cancers through objective testing. our team works with outstanding members of the oncology community throughout the discovery, development and utilization of these tests. currently, castle biosciences has tests to help doctors treat cutaneous melanoma, uveal melanoma, esophageal adenocarcinoma, mesothelioma and glioma. we have active research programs in rectal cancer and soft tissue sarcoma, and anticipate tests for these and other under-served cancers to be available in the near future please visit us at www.castlebiosciences.com for more information on our company and products.
Company profile
Ticker
CSTL
Exchange
Website
CEO
Derek J. Maetzold
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
AltheaDx, Inc. • Cernostics, Inc. • Myriad myPath, LLC ...
IRS number
770701744
CSTL stock data
Latest filings (excl ownership)
10-Q
2023 Q2
Quarterly report
2 Aug 23
8-K
Castle Biosciences Reports Second Quarter 2023 Results
2 Aug 23
8-K
Regulation FD Disclosure
5 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
1 Jun 23
DEFA14A
Additional proxy soliciting materials
15 May 23
10-Q
2023 Q1
Quarterly report
3 May 23
8-K
Castle Biosciences Reports First Quarter 2023 Results
3 May 23
ARS
2022 FY
Annual report to shareholders
12 Apr 23
DEFA14A
Additional proxy soliciting materials
12 Apr 23
DEF 14A
Definitive proxy
12 Apr 23
Transcripts
CSTL
Earnings call transcript
2023 Q2
2 Aug 23
CSTL
Earnings call transcript
2023 Q1
3 May 23
CSTL
Earnings call transcript
2022 Q4
28 Feb 23
CSTL
Earnings call transcript
2022 Q3
2 Nov 22
CSTL
Earnings call transcript
2022 Q2
12 Aug 22
CSTL
Earnings call transcript
2022 Q1
10 May 22
CSTL
Earnings call transcript
2021 Q4
1 Mar 22
CSTL
Earnings call transcript
2021 Q3
9 Nov 21
CSTL
Earnings call transcript
2021 Q2
11 Aug 21
CSTL
Earnings call transcript
2021 Q1
11 May 21
Latest ownership filings
Financial summary
| Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 95.87 mm | 95.87 mm | 95.87 mm | 95.87 mm | 95.87 mm | 95.87 mm |
| Cash burn (monthly) | 6.32 mm | 14.77 mm | 7.05 mm | 8.09 mm | 1.26 mm | 3.37 mm |
| Cash used (since last report) | 18.32 mm | 42.85 mm | 20.45 mm | 23.46 mm | 3.66 mm | 9.78 mm |
| Cash remaining | 77.56 mm | 53.02 mm | 75.42 mm | 72.42 mm | 92.21 mm | 86.10 mm |
| Runway (months of cash) | 12.3 | 3.6 | 10.7 | 9.0 | 73.1 | 25.5 |
Institutional ownership, Q2 2023
94.0% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 130 |
| Opened positions | 17 |
| Closed positions | 35 |
| Increased positions | 67 |
| Reduced positions | 25 |
| 13F shares | Current |
|---|---|
| Total value | 304.59 bn |
| Total shares | 25.21 mm |
| Total puts | 45.90 k |
| Total calls | 18.80 k |
| Total put/call ratio | 2.4 |
| Largest owners | Shares | Value |
|---|---|---|
| Wasatch Advisors | 3.09 mm | $42.35 bn |
| Granahan Investment Management | 2.53 mm | $34.70 bn |
| BLK Blackrock | 2.13 mm | $29.25 bn |
| Vanguard | 1.43 mm | $19.58 bn |
| PFG Principal Financial Group Inc - Registered Shares | 1.36 mm | $18.66 bn |
| BLVGF Bellevue | 1.12 mm | $15.42 bn |
| Millennium Management | 1.04 mm | $14.21 bn |
| Sofinnova HealthQuest Partners | 983.58 k | $52.32 mm |
| Bradbury Daniel | 743.42 k | $49.92 mm |
| Kornitzer Capital Management | 648.22 k | $8.89 bn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 Sep 23 | Bradbury Daniel | Common Stock | Sell | Dispose S | Yes | Yes | 20.04 | 360 | 7.21 k | 65,062 |
| 1 Sep 23 | Bradbury Daniel | Common Stock | Sell | Dispose S | Yes | Yes | 20.04 | 360 | 7.21 k | 65,037 |
| 1 Sep 23 | Bradbury Daniel | Common Stock | Sell | Dispose S | Yes | Yes | 20.04 | 1,082 | 21.68 k | 101,305 |
| 1 Sep 23 | Maetzold Derek J | Common Stock | Sell | Dispose S | Yes | Yes | 20.052 | 83 | 1.66 k | 16,646 |
| 1 Sep 23 | Maetzold Derek J | Common Stock | Sell | Dispose S | Yes | Yes | 20.052 | 83 | 1.66 k | 16,652 |
| 1 Sep 23 | Maetzold Derek J | Common Stock | Sell | Dispose S | Yes | Yes | 20.052 | 83 | 1.66 k | 16,652 |
| 1 Sep 23 | Maetzold Derek J | Common Stock | Sell | Dispose S | Yes | Yes | 20.052 | 81 | 1.62 k | 16,653 |
| 1 Sep 23 | Maetzold Derek J | Common Stock | Sell | Dispose S | Yes | Yes | 20.052 | 226 | 4.53 k | 94,748 |
| 1 Sep 23 | Maetzold Derek J | Common Stock | Sell | Dispose S | Yes | Yes | 20.052 | 226 | 4.53 k | 105,853 |
| 1 Sep 23 | Maetzold Derek J | Common Stock | Sell | Dispose S | No | Yes | 20.052 | 718 | 14.40 k | 115,103 |
News
Castle Biosciences Announced Late Saturday, Drug-Drug Interactions And Lifestyle Factors With Drug-Gene Interactions Provided By Castle's' IDgenetix Test Impacted the Number Of Drug Recommendations For Patients With Moderate to Severe Depression
10 Sep 23
Keybanc Maintains Overweight on Castle Biosciences, Lowers Price Target to $25
4 Aug 23
Clorox, Boot Barn, Herbalife, Upwork And Other Big Stocks Moving Higher On Thursday
3 Aug 23
Castle Biosciences Q2 EPS $(0.70) Beats $(1.01) Estimate, Sales $50.14M Beat $43.51M Estimate
2 Aug 23
Castle Biosciences's Earnings: A Preview
1 Aug 23
Press releases
Castle Biosciences, Leading Skin Cancer Expert, Darrell Rigel, M.D., M.S., and IMPACT Melanoma Board Member to Ring Nasdaq Closing Bell on Sept. 27, 2023, to Raise Awareness of Melanoma
25 Sep 23
Castle Biosciences Ranked Third Among 2023 Top Workplaces in the Healthcare Industry
19 Sep 23
TissueCypher® Barrett's Esophagus Test Outperformed Standard of Care in Risk-Stratifying Patients with Barrett's Esophagus
14 Sep 23
Castle Biosciences Announces Receipt of New York Laboratory Permit for Pittsburgh Laboratory
12 Sep 23
Integrating Drug-Drug Interactions and Lifestyle Factors with Drug-Gene Interactions Provided by Castle Biosciences' IDgenetix® Test Significantly Impacted the Number of Drug Recommendations for Patients with Moderate to Severe Depression
9 Sep 23